Loading...
•
Jun 30
LifeStance Q2 2025 Earnings Report
LifeStance reported strong second quarter 2025 results with double-digit revenue growth, increased clinician base, and significant improvements in net loss and Adjusted EBITDA.
Key Takeaways
LifeStance Health Group delivered a robust performance in the second quarter of 2025, with revenue increasing by 11% to $345.3 million. The company significantly reduced its net loss from $23.3 million in Q2 2024 to $3.8 million in Q2 2025, and saw a 19% increase in Adjusted EBITDA to $34.0 million. The clinician base expanded by 11% to 7,708, contributing to a 12% rise in visit volumes.
Revenue increased by 11% year-over-year to $345.3 million, driven by higher visit volumes and clinician growth.
Net loss significantly improved by 84% to $3.8 million, compared to a net loss of $23.3 million in the prior-year period.
Adjusted EBITDA grew by 19% to $34.0 million, with Adjusted EBITDA margin improving to 9.8% of total revenue.
The clinician base expanded to 7,708 clinicians, a net increase of 173 in the quarter, and visit volumes rose by 12% to 2.2 million.
LifeStance
LifeStance
Forward Guidance
LifeStance is reiterating its full-year 2025 revenue guidance and raising its expectations for Center Margin and Adjusted EBITDA, reflecting confidence in continued operational improvements and growth.
Positive Outlook
- Reiterating full year 2025 revenue guidance of $1.40 billion to $1.44 billion.
- Raising full year 2025 Center Margin expectations to $441 million to $465 million.
- Raising full year 2025 Adjusted EBITDA expectations to $140 million to $150 million.
- Expected Q3 2025 total revenue of $345 million to $365 million.
- Expected Q3 2025 Adjusted EBITDA of $33 million to $39 million.